Table 2. Ongoing immunotherapy studies in SCLC.
| Name | Study arms | Phase |
|---|---|---|
| LS-SCLC | ||
| STIMULI | Nivolumab+ ipilimumab maintenance vs. observation | II |
| NCT02402920 | Platinum/etoposide + radiation +/– pembrolizumab | I |
| ES-SCLC Treatment naïve | ||
| REACTION | Platinum/etoposide +/– pembrolizumab | II |
| KEYNOTE 604 | Platinum/etoposide +/– pembrolizumab | III |
| IMpower133 | Carboplatin/etoposide +/– atezolizumab | III |
| Caspian | Platinum/etoposide+ durvalumab +/– tremelimumab vs. chemotherapy alone | III |
| MCC-18914 | Platinum/etoposide followed by thoracic radiation +/– nivolumab +ipilimumab | I/II |
| NCT02402920 | Platinum/etoposide followed by thoracic radiation +/– pembrolizumab | I |
| ES-SCLC Maintenance | ||
| Checkmate 451 | Nivolumab, nivolumab + ipilimumab, placebo | III |
| ES-SCLC Subsequent lines | ||
| AFT17 | Pembrolizumab vs. topotecan | II |
| Checkmate 331 | Nivolumab vs. topotecan or amrubicin | III |
| IFCT-1603 | Atezolizumab vs. topotecan or carboplatin/etoposide | II |
| MISP-MK3475 | Pembrolizumab + paclitaxel | II |
| PembroPlus | Pembrolizumab + irinotecan | I/II |
| CA001-030 | BMS-986012 +/– nivolumab | I/II |
| KEYNOTE 158 | Pembrolizumab | II |
| NCT02937818 | Durvalumab + tremelimumab vs. AZD1775+carboplatin | II |
| Winship 3112-15 | Tremelimumab + durvalumab +/– radiation | II |
| M16-300 | Nivolumab + rovalpituzumab +/– ipilimumab | I |
| AAAQ8257 | SGI-110 followed by durvalumab + tremelimumab | I |
ES-SCLC, extensive stage small cell lung cancer; LS, limited stage.